Anavex Life Sciences to Announce Fiscal 2024 Fourth Quarter Financial Results on Monday, December 23, 2024
Anavex Life Sciences (Nasdaq: AVXL) announced it will release its fiscal 2024 fourth quarter financial results on Monday, December 23, 2024. The company will host a conference call and webcast at 8:30 am ET on the same day, where management will review financial results and provide updates on the company's growth strategy. The event will include a Q&A session and will be accessible via webcast on www.anavex.com or by phone for U.S. participants.
Anavex is a clinical-stage biopharmaceutical company developing treatments for various CNS disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other neurodegenerative and rare diseases.
Anavex Life Sciences (Nasdaq: AVXL) ha annunciato che rilascerà i suoi risultati finanziari del quarto trimestre fiscale 2024 lunedì 23 dicembre 2024. L'azienda ospiterà una teleconferenza e una trasmissione web alle 8:30 ET dello stesso giorno, in cui la direzione esaminerà i risultati finanziari e fornirà aggiornamenti sulla strategia di crescita dell'azienda. L'evento includerà una sessione di domande e risposte e sarà accessibile tramite web su www.anavex.com o telefonicamente per i partecipanti americani.
Anavex è un'azienda biopharma in fase clinica che sviluppa trattamenti per vari disturbi del SNC, tra cui la malattia di Alzheimer, la malattia di Parkinson, la schizofrenia, la sindrome di Rett e altre malattie neurodegenerative e rare.
Anavex Life Sciences (Nasdaq: AVXL) anunció que publicará sus resultados financieros del cuarto trimestre fiscal 2024 el lunes 23 de diciembre de 2024. La compañía llevará a cabo una conferencia telefónica y una transmisión web a las 8:30 am ET ese mismo día, donde la dirección revisará los resultados financieros y proporcionará actualizaciones sobre la estrategia de crecimiento de la empresa. El evento incluirá una sesión de preguntas y respuestas y será accesible a través de la transmisión web en www.anavex.com o por teléfono para los participantes de EE. UU.
Anavex es una empresa biofarmacéutica en etapa clínica que desarrolla tratamientos para varios trastornos del SNC, incluyendo la enfermedad de Alzheimer, la enfermedad de Parkinson, la esquizofrenia, el síndrome de Rett, y otras enfermedades neurodegenerativas y raras.
아나벡스 라이프 사이언스 (Nasdaq: AVXL)은 2024 회계연도 4분기 재무 결과를 2024년 12월 23일 월요일에 발표할 예정이라고 발표했습니다. 회사는 같은 날 오전 8:30 ET에 컨퍼런스 콜 및 웹캐스트를 개최하며, 경영진이 재무 결과를 검토하고 회사의 성장 전략에 대한 업데이트를 제공할 것입니다. 이 이벤트에는 Q&A 세션이 포함되어 있으며, www.anavex.com을 통해 웹캐스트로 또는 미국 참가자들을 위해 전화로 접근할 수 있습니다.
아나벡스는 알츠하이머병, 파킨슨병, 조현병, 레트 증후군 등 다양한 CNS 질환을 위한 치료제를 개발하는 임상 단계의 생명공학 회사입니다.
Anavex Life Sciences (Nasdaq: AVXL) a annoncé qu'elle publiera ses résultats financiers du quatrième trimestre de l'exercice 2024 le lundi 23 décembre 2024. L'entreprise organisera une conférence téléphonique et une diffusion en direct à 8h30 ET le même jour, où la direction examinera les résultats financiers et fournira des mises à jour sur la stratégie de croissance de l'entreprise. L'événement comprendra une session de questions-réponses et sera accessible par le biais du web sur www.anavex.com ou par téléphone pour les participants américains.
Anavex est une entreprise biopharmaceutique en phase clinique développant des traitements pour divers troubles du SNC, y compris la maladie d'Alzheimer, la maladie de Parkinson, la schizophrénie, le syndrome de Rett, ainsi que d'autres maladies neurodégénératives et rares.
Anavex Life Sciences (Nasdaq: AVXL) gab bekannt, dass es seine finanziellen Ergebnisse für das vierte Quartal des Geschäftsjahres 2024 am Montag, den 23. Dezember 2024, herausgeben wird. Das Unternehmen wird am selben Tag um 8:30 Uhr ET eine Telefonkonferenz und ein Webcast veranstalten, in dem das Management die finanziellen Ergebnisse überprüfen und Updates zur Wachstumsstrategie des Unternehmens bereitstellen wird. Die Veranstaltung umfasst eine Fragen-und-Antworten-Sitzung und ist über die Webseite www.anavex.com oder telefonisch für amerikanische Teilnehmer zugänglich.
Anavex ist ein biopharmazeutisches Unternehmen in der klinischen Phase, das Behandlungen für verschiedene ZNS-Störungen entwickelt, einschließlich Alzheimer-Krankheit, Parkinson-Krankheit, Schizophrenie, Rett-Syndrom und andere neurodegenerative und seltene Krankheiten.
- None.
- None.
Webcast and Conference Call To be Held Monday, December 23, 2024, 8:30 am ET
NEW YORK, Dec. 16, 2024 (GLOBE NEWSWIRE) -- Anavex Life Sciences Corp. (“Anavex” or the “Company”) (Nasdaq: AVXL), a clinical-stage biopharmaceutical company focused on developing innovative treatments for Alzheimer's disease, Parkinson's disease, schizophrenia, neurodevelopmental, neurodegenerative, and rare diseases, including Rett syndrome, and other central nervous system (CNS) disorders, today announced that it will issue financial results for its fiscal year ended September 30, 2024, on Monday, December 23, 2024.
Management will host a conference call on Monday, December 23, at 8:30 am ET to review financial results and provide an update on the execution of the Company’s growth strategy. Following management’s remarks, there will be a question-and-answer session.
Webcast / Conference Call Information:
The live webcast of the conference call will be available on Anavex’s website at www.anavex.com.
The conference call can be also accessed by dialing 1 929 205 6099 for participants in the U.S. using the Meeting ID# 814 6482 4038 and reference passcode 336064. A replay of the conference call will also be available on Anavex’s website for up to 30 days.
About Anavex Life Sciences Corp.
Anavex Life Sciences Corp. (Nasdaq: AVXL) is a publicly traded biopharmaceutical company dedicated to the development of novel therapeutics for the treatment of neurodegenerative, neurodevelopmental, and neuropsychiatric disorders, including Alzheimer's disease, Parkinson's disease, schizophrenia, Rett syndrome, and other central nervous system (CNS) diseases, pain, and various types of cancer. Anavex's lead drug candidate, ANAVEX®2-73 (blarcamesine), has successfully completed a Phase 2a and a Phase 2b/3 clinical trial for Alzheimer's disease, a Phase 2 proof-of-concept study in Parkinson's disease dementia, and both a Phase 2 and a Phase 3 study in adult patients and one Phase 2/3 study in pediatric patients with Rett syndrome. ANAVEX®2-73 is an orally available drug candidate designed to restore cellular homeostasis by targeting SIGMAR1 and muscarinic receptors. Preclinical studies demonstrated its potential to halt and/or reverse the course of Alzheimer's disease. ANAVEX®2-73 also exhibited anticonvulsant, anti-amnesic, neuroprotective, and anti-depressant properties in animal models, indicating its potential to treat additional CNS disorders, including epilepsy. The Michael J. Fox Foundation for Parkinson's Research previously awarded Anavex a research grant, which fully funded a preclinical study to develop ANAVEX®2-73 for the treatment of Parkinson's disease. We believe that ANAVEX®3-71, which targets SIGMAR1 and M1 muscarinic receptors, is a promising clinical stage drug candidate demonstrating disease-modifying activity against the major hallmarks of Alzheimer's disease in transgenic (3xTg-AD) mice, including cognitive deficits, amyloid, and tau pathologies. In preclinical trials, ANAVEX®3-71 has shown beneficial effects on mitochondrial dysfunction and neuroinflammation. Further information is available at www.anavex.com. You can also connect with the Company on Twitter, Facebook, Instagram, and LinkedIn.
Forward-Looking Statements
Statements in this press release that are not strictly historical in nature are forward-looking statements. These statements are only predictions based on current information and expectations and involve a number of risks and uncertainties. Actual events or results may differ materially from those projected in any of such statements due to various factors, including the risks set forth in the Company’s most recent Annual Report on Form 10-K filed with the SEC. Readers are cautioned not to place undue reliance on these forward-looking statements, which speak only as of the date hereof. All forward-looking statements are qualified in their entirety by this cautionary statement and Anavex Life Sciences Corp. undertakes no obligation to revise or update this press release to reflect events or circumstances after the date hereof.
For Further Information:
Anavex Life Sciences Corp.
Research & Business Development
Toll-free: 1-844-689-3939
Email: info@anavex.com
Investors:
Andrew J. Barwicki
Investor Relations
Tel: 516-662-9461
Email: andrew@barwicki.com
FAQ
When will Anavex Life Sciences (AVXL) report Q4 2024 earnings?
What time is AVXL's Q4 2024 earnings call?
How can investors access AVXL's Q4 2024 earnings call?
What diseases is AVXL currently developing treatments for?
